switching tirzepatide to semaglutide How Switch from to switching from semaglutide to tirzepatide
Description
The UK SmPC includes warnings and precautions regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans
De dosering wordt opgebouwd van 2,5 mg naar 15 mg per week, afhankelijk van effect en bijwerkingen
Administration of GLP- 1 receptor agonists reduces appetite, decreases energy intake, and increases satiety
Dosing usually begins at a low level to reduce initial side effects and increases gradually to achieve optimal metabolic benefits
Side Effects Common: Nausea, vomiting, diarrhea, constipation, abdominal discomfort, decreased appetite, headache
